Business
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update
- Appointed Michael Amoroso as President and Chief Executive Officer and to Board of Directors; Sam Wadsworth, Ph.D., and Shari Lisa Piré, J.D., Appointed to
About this update from Precision Biosciences, Inc.
[{"type":"text","content":"\n- Appointed Michael Amoroso as President and Chief Executive Officer and to Board of Directors; Sam Wadsworth, Ph.D., and Shari Lisa Piré, J.D., Appointed to Board of Directors\n\n- Hosted In Vivo Gene Editing R&D Event and Outlined Plans for Accelerated Path to Clinic for Three Investigational New Drug/Clinical Trial Applications Within Next Three Years\n\n- Announced In Vivo Gene Editing License and Collaboration Agreement with iECURE to Advance Precision BioSciences’ Wholly-Owned PCSK9 Program for Familial Hypercholesterolemia Through Phase 1 and Develop Four ARCUS-Based Gene Insertion Programs\n\n- Company to Present Interim Data from PBCAR0191 Allogeneic CAR T Program During Two Oral Presentations at Upcoming American Society of Hematology Annual Meeting; Company to Host Webcast on Saturday, December 11, 2021 to Provide a CAR T Portfolio Update\n\n DURHAM, N.C.--(BUSINESS WIRE)--\nPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2021 and provided a business update.\n\n“Precision is dedicated to delivering on the vast potential of ARCUS gene editing for best-in-class cell and gene therapeutics. In addition to significant research and development progress this past quarter, we signed strategic license and development agreements that we believe are accelerating certain in vivo program timelines to the clinic and providing us with important optionality for future product development efforts,” said Michael Amoroso, Chief Executive Officer at Precision BioSciences.\n\n“During our in vivo gene editing event in September, we showcased data supporting ARCUS’ differentiating capabilities for gene knockout, gene insertion and gene repair, and mitochondrial DNA gene editing. We also outlined an in vivo gene editing clinical development strategy designed to advance three investigational new drug (IND) or clinical trial applications (CTA) over the next three years. In addition, we continue to actively recruit patients for our ongoing clinical studies with PBCAR0191, PBCAR19B, and PBCAR269A while monitoring for safety, overall response rate, and durability of response. We look forward to sharing updated data on the PBCAR0191 ...